- Study, every finding
- meta-analysis
No finding here moved its endpoint.
What did not
How to read these marks →“In a meta-analysis of two high quality long-term trials (n = 582), Serenoa repens therapy was not superior to placebo in reducing LUTS based on the AUA (mean difference (MD) 0.25 points, 95% confidence interval (CI) -0.58 to 1.07).”
- Participants
- 582
- Effect
- 0.25 mean difference, 95% CI −0.58 to 1.07
- Population
- Men with lower urinary tract symptoms consistent with benign prostatic hyperplasia; pooled two high quality long-term trials
“The three high quality, moderate-to-long term trials found peak urine flow was not improved with Serenoa repens compared with placebo (MD 0.40 mL/s, 95% CI -0.30 to 1.09).”
- Effect
- 0.4 mean difference, 95% CI −0.3 to 1.09
- Population
- Men with lower urinary tract symptoms consistent with benign prostatic hyperplasia; pooled three high quality moderate-to-long term trials
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Men with symptomatic benign prostatic hyperplasia / LUTS; Serenoa repens preparations (alone or in combination) versus placebo or other interventions, 32 randomized trials
- Participants
- 5,666
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 6